A phase I study of novel dual Bcl-2/Bcl-xL inhibitor APG-1252 in patients with advanced small cell lung cancer (SCLC) or other solid tumor

MLA

Lichuang Men, et al. “A Phase I Study of Novel Dual Bcl-2/Bcl-XL Inhibitor APG-1252 in Patients with Advanced Small Cell Lung Cancer (SCLC) or Other Solid Tumor.” Journal of Clinical Oncology, vol. 36, May 2018, p. 2594. EBSCOhost, https://doi.org/10.1200/jco.2018.36.15_suppl.2594.

APA

Lichuang Men, Sreenivasa R Chandana, Yvette Cole, Yingjie Huang, Hengbang Wang, Nehal Lakhani, Kyriakos P. Papadopoulos, Timothy J. O’Rourke, Anthony W. Tolcher, Amita Patnaik, Qi Dong, Jiao Ji, Alex Amaya, Dajun Yang, Theresa Mays, Drew W. Rasco, Yifan Zhai, & Brianne Kaiser. (2018). A phase I study of novel dual Bcl-2/Bcl-xL inhibitor APG-1252 in patients with advanced small cell lung cancer (SCLC) or other solid tumor. Journal of Clinical Oncology, 36, 2594. https://doi.org/10.1200/jco.2018.36.15_suppl.2594

Chicago

Lichuang Men, Sreenivasa R Chandana, Yvette Cole, Yingjie Huang, Hengbang Wang, Nehal Lakhani, Kyriakos P. Papadopoulos, et al. 2018. “A Phase I Study of Novel Dual Bcl-2/Bcl-XL Inhibitor APG-1252 in Patients with Advanced Small Cell Lung Cancer (SCLC) or Other Solid Tumor.” Journal of Clinical Oncology 36 (May): 2594. doi:10.1200/jco.2018.36.15_suppl.2594.